title: New modalities in the chronic ischemic diabetic foot management.
abstract: The diabetic population is increasing worldwide at a staggering rate. Diabetic foot ulcers are a major contributor to nontraumatic lower limb amputations and peripheral arterial disease is one of main contributing pathophysiologic causes of diabetic ulcers. The dire need to reduce complication and wound healing recovery period of the chronic ischemic diabetic foot (CIDF) is indispensable to limb salvage and improvement of quality of life of patients with CIDF. This article discusses newer modalities that have been proposed to improve CIDF efficiently, safely, and effectively either alone or as adjuvants to conventional therapy.
authors.affiliation: Department of Vascular Surgery, Yale University School of Medicine, 310 Cedar Street, New Haven, CT 06510, USA.
authors.forename: Sherif Y
authors.initials: SY
authors.lastname: Shalaby
authors.forename: Peter
authors.initials: P
authors.lastname: Blume
authors.forename: Bauer E
authors.initials: BE
authors.lastname: Sumpio
mesh_terms: D064987:Cell- and Tissue-Based Therapy; D017719:Diabetic Foot / Q000628:therapy*; D004815:Epidermal Growth Factor / Q000627:therapeutic use; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D006801:Humans; D011453:Prostaglandins / Q000627:therapeutic use
chemical_list: D005343:Fibrinolytic Agents; D011453:Prostaglandins; D016179:Granulocyte Colony-Stimulating Factor; D004815:Epidermal Growth Factor
keywords: Critical limb ischemia; Diabetic foot; Future perspectives; Therapy